A Phase 3 interventional study of 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 and Placebo in Psoriasis, sponsored by Eli Lilly and Company. Completed at 104 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-03.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing ixekizumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. ixekizumab · Psoriasis.
Among the 22 studies testing ixekizumab in Psoriasis, this one is the 2nd largest by enrollment, is the only one that started in 2011, is one of 11 in phase 3, and was the 2nd registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 22 studies testing ixekizumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
Singapore General Hospital · Sites in Singapore
Ages 22–90
University of California, San Francisco · Sites in United States
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University
Ages 70+
By country, each count listing its studies:
ixekizumab: first FDA approval 2016 (TALTZ), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,296 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 156 across the 22 interventional studies. Of the 17 that completed or were terminated, 16 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 22 have an industry lead sponsor. The 6 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
36 studies in Psoriasis by Eli Lilly and Company: 1 open now, 1 under way, none of them phase 3. Of 35 finished, 28 (80%) have results posted.
Among the 36 studies in Psoriasis by Eli Lilly and Company, this one is the 4th largest by enrollment, is one of 2 that started in 2011, is one of 15 in phase 3, and was the 3rd registered.
Eli Lilly and Company’s Psoriasis studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing ixekizumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 36 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the safety and efficacy of LY2439821 compared to placebo in participants with moderate to severe, chronic plaque psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered as two 80-mg subcutaneous (SC) injections at Week 0, then one 80-mg SC injection per Dosing Regimen 1 \[every 2 weeks (Q2W)\] up to and including Week 10. At Week 12, arm is re-randomized to placebo, Dosing Regimen 2 \[every 4 weeks (Q4W)\] or Dosing Regimen 3 \[every 12 weeks Q12W)\].
Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3
Administered as two 80-mg SC injections at Week 0, then one 80-mg SC injection per Dosing Regimen 2 (Q4W) up to and including Week 10. At Week 12, arm is re-randomized to placebo, Dosing Regimen 2 (Q4W) or Dosing Regimen 3 (Q12W).
Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3
Dosing Regimen 3 (Q12W) is not used until Week 12. At Week 12, participants who were re-randomized to this arm were administered one 80-mg SC injection Q12W.
Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3
Administered as 2 SC injections at Week 0, then 1 SC injection per Dosing Regimen 1 (Q2W) up to and including Week 10. At Week 12, arm is re-randomized to placebo or Dosing Regimen 2 (Q4W).
Drug: Placebo
Drug page: Ixekizumab
Administered SC
Also known as: LY2439821
Administered SC
Percentage of Participants With Static Physician Global Assessment (sPGA) of 0 or 1 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA)
The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline.
Time frame: Week 12
Percentage of Participants Achieving ≥75% Improvement in Ps Area and Severity Index (PASI75) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis Measure: PASI)
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI75 were defined as having an improvement of ≥75% in the PASI score compared to baseline.
Time frame: Week 12
Percentage of Participants Achieving an sPGA of 0 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA)
The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).
Time frame: Week 12
Percentage of Participants Achieving PASI 90% (PASI90) or 100% (PASI100) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: PASI)
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI90 or PASI100 were defined as having an improvement of ≥90% or of 100% respectively in PASI scores compared to baseline.
Time frame: Week 12
Percentage of Participants Maintaining sPGA 0 or 1 After Re-Randomization at Start of Maintenance Dosing Period
The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).
Time frame: Week 60
Percentage of Participants With Itch Numeric Rating Scale (Itch NRS) Score ≥4 Point Reduction From Baseline
The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 (no itch) and 10 (worst itch imaginable). Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.
Time frame: Baseline, Week 12
Change From Baseline in Dermatology-Specific Quality of Life Index (DLQI) Score
DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much) and unanswered ("not relevant") responses were scored as "0." Total scores range from 0 to 30, with higher score indicating greater quality of life is impairment. A 5-point change from baseline is considered clinically relevant. Least squares (LS) mean change from baseline was calculated using mixed model repeated measures (MMRM).
Time frame: Baseline, Week 12
Change From Baseline in Nail Psoriasis Severity Index (NAPSI)
The NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail Ps. This scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps by area of involvement in the fingernail unit. The fingernail is divided with imaginary horizontal and longitudinal lines into quadrants. Each fingernail is given a score for fingernail bed Ps 0 (none) to 4 (Ps in 4 quadrants of the fingernail) and fingernail matrix Ps 0 (none) to 4 (Ps in 4 quadrants of the matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix Ps in each quadrant. The NAPSI score of a fingernail is the sum of scores in fingernail bed and fingernail matrix from each quadrant (maximum of 8). Each fingernail is evaluated, then the sum of all fingernails equals the total NAPSI score with a range from 0 to 80 with higher scores indicating more severe psoriasis. LS mean change from baseline was calculated using MMRM.
Time frame: Baseline, Week 12
Percent of Body Surface Area (BSA) Involvement of Ps
BSA is a physician rating of the percentage of involvement of Ps for each participant. BSA is assessed on a continuous scale from 0% (no involvement) to 100% (full involvement), where 1% corresponds to the size of the participants hand (includes the palm, fingers and thumb). Total BSA is the sum of handprints from the affected areas. LS mean change from baseline was calculated using MMRM.
Time frame: Week 12
Change From Baseline in Psoriasis Scalp Severity Index (PSSI)
The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total scores range from 0 to 72, with lower scores indicating less severity. LS mean change from baseline was calculated using MMRM.
Time frame: Baseline, Week 12
Change From Baseline in All Scores of the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO) Quality of Life and Outcome Assessments. Measures: Participant Reported Outcomes (PRO)
WPAI-PSO is a participant administered, 6-item instrument used to assess the impact of Ps on the productivity impairment within the past 7 days. WPAI-PSO has 4 domains: absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score, and impairment in daily activities performed outside of work. Four scores are derived as percentages: absenteeism, presenteeism (reduced productivity while at work), overall work impairment (absenteeism and presenteeism), and impairment in activities performed outside of work. Percentage is calculated as: each score \* 100 with greater scores indicating greater impairment. LS mean change from baseline was calculated using analysis of covariance (ANCOVA).
Time frame: Baseline, Week 12
Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Reported 16 Items (QIDS-SR16)
QIDS-SR16 is a participant-administered, 16-item instrument intended to assess the existence and severity of symptoms of depression. A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days and rate each on a 4-point scale: 0 (best) to 3 (worst). The sum of the 16 items corresponding to 9 depression domains \[sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance (initial, middle and late insomnia or hypersomnia), decrease/increase in appetite/weight, and psychomotor agitation/retardation\] to give a single total scores range from 0 to 27, with higher scores indicating greater symptom severity. LS mean change from baseline was calculated using ANCOVA.
Time frame: Baseline, Week 12
Change From Baseline in Medical Outcomes Study 36-item Short Form Health Survey (SF-36) and Physical Component Summary (PCS) and Mental Component Summary (MCS)
The SF-36 is a self-reported instrument that measures the participant's health status during the previous 7 days. It comprises 36-items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped in the PCS and MCS scores. Scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS mean change from baseline was calculated using ANCOVA.
Time frame: Baseline, Week 12
Change From Baseline in Patient's Global Assessment of Disease Severity (PatGA)
The PatGA is a single-item self-reported instrument asking the participant to rate the severity of their psoriasis "today" by circling a number on the numeric rating scale from 0 (Clear = no psoriasis) to 5 (Severe = the worst their psoriasis has ever been). LS mean change from baseline calculated using MMRM.
Time frame: Baseline, Week 12
Percentage of Participants Achieving Palmoplantar PASI (PPASI) of ≥50% (PPASI50), ≥75% (PPASI75), or 100% (PPASI100) Improvement
The Palmoplantar PASI is a composite score derived from the sum of scores for erythema, induration, and desquamation \[scores range from 0 (none) to 4 (very severe) for each\] multiplied by the score for the extent of palm and sole area involvement \[scores range from 0 (0%) to 6 (90 to100%)\], with a total scores range from 0 to 72. Participants achieving PPASI50, PPASI75 or PASI100 were defined as having an improvement of at least 50%, 90%, or of 100%, respectively, in the PPASI scores compared to baseline.
Time frame: Week 12
Pharmacokinetics (PK): Trough Concentration at Steady State (Ctrough ss)
Time frame: Weeks 12: Day 84 and Week 24: Day 168
Percentage of Participants With Anti-ixekizumab Antibodies
Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.
Time frame: Baseline through Week 12
Induction Period (Week 0 to 12), Maintenance Period (Week 12 to 60); Long term Extension (Week 60 to 264) and Post treatment ( last treatment visit (week 264), or Early Termination Visit (ETV) up to a minimum of 12 weeks following that visit.
| Milestone | Placebo- Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period | Ixe/Placebo- Maintenance Period Primary Pop | Ixe/Ixe Q12W - Maintenance Period Primary Pop | Ixe/Ixe Q4W - Maintenance Period Primary Pop | Placebo Resp/Placebo - Maintenance Period Secondary Pop | Placebo Non-Resp/Ixe Q4W - Maintenance Period Secondary Pop | Ixe Q4W Non-Resp/Ixe Q4W- Maintenance Period Secondary Pop | Q2W Non-Resp/Q4W - Maintenance Period Secondary Pop | Ixe Q4W - Maintenance Period Relapsed Population | Placebo Long-Term Extension (LTE) | Ixe Long-Term Extension | Total Ixe Long-Term Extension | Placebo Post-Treatment Follow-Up | Ixe Q12W Post-Treatment Follow-Up | Ixe Q4W Post-Treatment Follow-Up | Ixe Q2W Post-Treatment Follow-Up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 431 | 432 | 433 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received study drug | 431 | 432 | 433 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 407 | 408 | 415 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 24 | 24 | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 6 | 10 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 7 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 6 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 3 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo- Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period | Ixe/Placebo- Maintenance Period Primary Pop | Ixe/Ixe Q12W - Maintenance Period Primary Pop | Ixe/Ixe Q4W - Maintenance Period Primary Pop | Placebo Resp/Placebo - Maintenance Period Secondary Pop | Placebo Non-Resp/Ixe Q4W - Maintenance Period Secondary Pop | Ixe Q4W Non-Resp/Ixe Q4W- Maintenance Period Secondary Pop | Q2W Non-Resp/Q4W - Maintenance Period Secondary Pop | Ixe Q4W - Maintenance Period Relapsed Population | Placebo Long-Term Extension (LTE) | Ixe Long-Term Extension | Total Ixe Long-Term Extension | Placebo Post-Treatment Follow-Up | Ixe Q12W Post-Treatment Follow-Up | Ixe Q4W Post-Treatment Follow-Up | Ixe Q2W Post-Treatment Follow-Up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 226 | 227 | 229 | 16 | 391 | 78 | 62 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received study drug | 0 | 0 | 0 | 226 | 227 | 229 | 16 | 391 | 78 | 62 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Relapsed population received drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 348 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Relapsed population completers | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 321 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 24 | 108 | 177 | 6 | 350 | 62 | 44 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 202 | 119 | 52 | 10 | 41 | 16 | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Relapsed (spga ≥3) | 0 | 0 | 0 | 186 | 111 | 39 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 4 | 2 | 7 | 0 | 19 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 6 | 2 | 3 | 1 | 6 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 3 | 3 | 0 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Clinical relapse | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 11 | 11 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Treated but discontinued in induction | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo- Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period | Ixe/Placebo- Maintenance Period Primary Pop | Ixe/Ixe Q12W - Maintenance Period Primary Pop | Ixe/Ixe Q4W - Maintenance Period Primary Pop | Placebo Resp/Placebo - Maintenance Period Secondary Pop | Placebo Non-Resp/Ixe Q4W - Maintenance Period Secondary Pop | Ixe Q4W Non-Resp/Ixe Q4W- Maintenance Period Secondary Pop | Q2W Non-Resp/Q4W - Maintenance Period Secondary Pop | Ixe Q4W - Maintenance Period Relapsed Population | Placebo Long-Term Extension (LTE) | Ixe Long-Term Extension | Total Ixe Long-Term Extension | Placebo Post-Treatment Follow-Up | Ixe Q12W Post-Treatment Follow-Up | Ixe Q4W Post-Treatment Follow-Up | Ixe Q2W Post-Treatment Follow-Up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26 | 1054 | 1075 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 836 | 855 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26 | 218 | 220 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 61 | 61 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 57 | 58 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 25 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 24 | 25 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 21 | 0 | 0 | 0 | 0 |
| Withdrew: Clinical relapse | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 9 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 9 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 5 | 0 | 0 | 0 | 0 |
| Withdrew: Parent/caregiver decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Switched from pbo to ixe | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo- Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period | Ixe/Placebo- Maintenance Period Primary Pop | Ixe/Ixe Q12W - Maintenance Period Primary Pop | Ixe/Ixe Q4W - Maintenance Period Primary Pop | Placebo Resp/Placebo - Maintenance Period Secondary Pop | Placebo Non-Resp/Ixe Q4W - Maintenance Period Secondary Pop | Ixe Q4W Non-Resp/Ixe Q4W- Maintenance Period Secondary Pop | Q2W Non-Resp/Q4W - Maintenance Period Secondary Pop | Ixe Q4W - Maintenance Period Relapsed Population | Placebo Long-Term Extension (LTE) | Ixe Long-Term Extension | Total Ixe Long-Term Extension | Placebo Post-Treatment Follow-Up | Ixe Q12W Post-Treatment Follow-Up | Ixe Q4W Post-Treatment Follow-Up | Ixe Q2W Post-Treatment Follow-Up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18 | 25 | 700 | 285 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17 | 544 | 239 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18 | 8 | 156 | 46 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 2 | 58 | 11 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 36 | 17 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 31 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 7 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 5 |
| Withdrew: Clinical relapse | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 2 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 4 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 4 | 0 |
| Withdrew: Parent/caregiver decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline.
| percentage of participants | Placebo | Ixe Q4W | Ixe Q2W |
|---|---|---|---|
| Percentage of Participants With Static Physician Global Assessment (sPGA) of 0 or 1 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA) | 3.2 | 76.4 | 81.8 |
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI75 were defined as having an improvement of ≥75% in the PASI score compared to baseline.
| percentage of participants | Placebo | Ixe Q4W | Ixe Q2W |
|---|---|---|---|
| Percentage of Participants Achieving ≥75% Improvement in Ps Area and Severity Index (PASI75) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis Measure: PASI) | 3.9 | 82.6 | 89.1 |
The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).
| percentage of participants | Placebo | Ixe Q4W | Ixe Q2W |
|---|---|---|---|
| Percentage of Participants Achieving an sPGA of 0 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA) | 0.0 | 34.5 | 37.0 |
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI90 or PASI100 were defined as having an improvement of ≥90% or of 100% respectively in PASI scores compared to baseline.
| percentage of participants | Placebo | Ixe Q4W | Ixe Q2W |
|---|---|---|---|
| PASI90 | 0.5 | 64.6 | 70.9 |
| PASI100 | 0.0 | 33.6 | 35.3 |
The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).
| percentage of participants | Ixe/Placebo | Ixe/Q12W | Ixe/Q4W |
|---|---|---|---|
| Percentage of Participants Maintaining sPGA 0 or 1 After Re-Randomization at Start of Maintenance Dosing Period | 7.5 | 37.4 | 72.9 |
The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 (no itch) and 10 (worst itch imaginable). Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.
| percentage of participants | Placebo | Ixe Q4W | Ixe Q2W |
|---|---|---|---|
| Percentage of Participants With Itch Numeric Rating Scale (Itch NRS) Score ≥4 Point Reduction From Baseline | 15.5 | 80.5 | 85.9 |
DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much) and unanswered ("not relevant") responses were scored as "0." Total scores range from 0 to 30, with higher score indicating greater quality of life is impairment. A 5-point change from baseline is considered clinically relevant. Least squares (LS) mean change from baseline was calculated using mixed model repeated measures (MMRM).
| units on a scale | Placebo | Ixe Q4W | Ixe Q2W |
|---|---|---|---|
| Change From Baseline in Dermatology-Specific Quality of Life Index (DLQI) Score | -1.0 ± 0.27 | -10.7 ± 0.27 | -11.1 ± 0.26 |
The NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail Ps. This scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps by area of involvement in the fingernail unit. The fingernail is divided with imaginary horizontal and longitudinal lines into quadrants. Each fingernail is given a score for fingernail bed Ps 0 (none) to 4 (Ps in 4 quadrants of the fingernail) and fingernail matrix Ps 0 (none) to 4 (Ps in 4 quadrants of the matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix Ps in each quadrant. The NAPSI score of a fingernail is the sum of scores in fingernail bed and fingernail matrix from each quadrant (maximum of 8). Each fingernail is evaluated, then the sum of all fingernails equals the total NAPSI score with a range from 0 to 80 with higher scores indicating more severe psoriasis. LS mean change from baseline was calculated using MMRM.
| units on a scale | Placebo | Ixe Q4W | Ixe Q2W |
|---|---|---|---|
| Change From Baseline in Nail Psoriasis Severity Index (NAPSI) | 2.17 ± 0.672 | -7.19 ± 0.671 | -7.24 ± 0.657 |
BSA is a physician rating of the percentage of involvement of Ps for each participant. BSA is assessed on a continuous scale from 0% (no involvement) to 100% (full involvement), where 1% corresponds to the size of the participants hand (includes the palm, fingers and thumb). Total BSA is the sum of handprints from the affected areas. LS mean change from baseline was calculated using MMRM.
| percentage of body surface | Placebo | Ixe Q4W | Ixe Q2W |
|---|---|---|---|
| Percent of Body Surface Area (BSA) Involvement of Ps | 1.3 ± 0.67 | -21.4 ± 0.67 | -22.4 ± 0.66 |
The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total scores range from 0 to 72, with lower scores indicating less severity. LS mean change from baseline was calculated using MMRM.
| units on a scale | Placebo | Ixe Q4W | Ixe Q2W |
|---|---|---|---|
| Change From Baseline in Psoriasis Scalp Severity Index (PSSI) | -1.8 ± 0.53 | -18.3 ± 0.52 | -19.2 ± 0.52 |
WPAI-PSO is a participant administered, 6-item instrument used to assess the impact of Ps on the productivity impairment within the past 7 days. WPAI-PSO has 4 domains: absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score, and impairment in daily activities performed outside of work. Four scores are derived as percentages: absenteeism, presenteeism (reduced productivity while at work), overall work impairment (absenteeism and presenteeism), and impairment in activities performed outside of work. Percentage is calculated as: each score \* 100 with greater scores indicating greater impairment. LS mean change from baseline was calculated using analysis of covariance (ANCOVA).
| units on a scale | Placebo | Ixe Q4W | Ixe Q2W |
|---|---|---|---|
| Absenteeism | 0.2 ± 0.88 | -3.5 ± 0.87 | -2.6 ± 0.84 |
| Activity Impairment | 0.8 ± 1.18 | -24.5 ± 1.18 | -25.2 ± 1.15 |
| Presenteeism | 0.5 ± 1.30 | -18.8 ± 1.28 | -18.3 ± 1.24 |
| Work Productivity Loss | -0.8 ± 1.40 | -20.6 ± 1.38 | -19.8 ± 1.33 |
QIDS-SR16 is a participant-administered, 16-item instrument intended to assess the existence and severity of symptoms of depression. A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days and rate each on a 4-point scale: 0 (best) to 3 (worst). The sum of the 16 items corresponding to 9 depression domains \[sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance (initial, middle and late insomnia or hypersomnia), decrease/increase in appetite/weight, and psychomotor agitation/retardation\] to give a single total scores range from 0 to 27, with higher scores indicating greater symptom severity. LS mean change from baseline was calculated using ANCOVA.
| units on a scale | Placebo | Ixe Q4W | Ixe Q2W |
|---|---|---|---|
| Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Reported 16 Items (QIDS-SR16) | -0.1 ± 0.17 | -1.0 ± 0.17 | -1.3 ± 0.17 |
The SF-36 is a self-reported instrument that measures the participant's health status during the previous 7 days. It comprises 36-items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped in the PCS and MCS scores. Scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS mean change from baseline was calculated using ANCOVA.
| units on a scale | Placebo | Ixe Q4W | Ixe Q2W |
|---|---|---|---|
| PCS | -0.1747 ± 0.4012 | 4.3081 ± 0.3990 | 4.3159 ± 0.3878 |
| MCS | 0.8729 ± 0.4638 | 3.7386 ± 0.4633 | 4.1293 ± 0.4480 |
The PatGA is a single-item self-reported instrument asking the participant to rate the severity of their psoriasis "today" by circling a number on the numeric rating scale from 0 (Clear = no psoriasis) to 5 (Severe = the worst their psoriasis has ever been). LS mean change from baseline calculated using MMRM.
| units on a scale | Placebo | Ixe Q4W | Ixe Q2W |
|---|---|---|---|
| Change From Baseline in Patient's Global Assessment of Disease Severity (PatGA) | -0.2 ± 0.06 | -3.1 ± 0.06 | -3.2 ± 0.06 |
The Palmoplantar PASI is a composite score derived from the sum of scores for erythema, induration, and desquamation \[scores range from 0 (none) to 4 (very severe) for each\] multiplied by the score for the extent of palm and sole area involvement \[scores range from 0 (0%) to 6 (90 to100%)\], with a total scores range from 0 to 72. Participants achieving PPASI50, PPASI75 or PASI100 were defined as having an improvement of at least 50%, 90%, or of 100%, respectively, in the PPASI scores compared to baseline.
| percentage of participants | Placebo | Ixe Q4W | Ixe Q2W |
|---|---|---|---|
| PPASI50 | 35.3 | 84.0 | 82.9 |
| PPASI75 | 26.3 | 74.8 | 77.1 |
| PPASI100 | 20.3 | 65.6 | 70.0 |
| micrograms/milliliter (µg/mL) | Ixe Q2W - Induction Period | Ixe Q4W - Induction Period | Ixe Q4W - Maintenance Period | Ixe Q12W - Maintenance Period |
|---|---|---|---|---|
| Week 12 | 7.73 ± 79 | 2.94 ± 89 | NA ± NA | NA ± NA |
| Week 24 | NA ± NA | NA ± NA | 2.36 ± 111 | 0.281 ± 175 |
Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.
| percentage of participants | Placebo | Ixe Q4W | Ixe Q2W |
|---|---|---|---|
| Percentage of Participants With Anti-ixekizumab Antibodies | 0.5 | 12.5 | 10.3 |
Collected over Up to 276 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo - Induction Period | — | 5/431 (1.2%) | 128/431 (29.7%) |
| Ixe Q4W - Induction Period | — | 12/432 (2.8%) | 159/432 (36.8%) |
| Ixe Q2W - Induction Period | — | 7/433 (1.6%) | 170/433 (39.3%) |
| Ixe/Placebo- Maintenance Period Primary Pop | — | 7/226 (3.1%) | 83/226 (36.7%) |
| Ixe/Ixe Q12W - Maintenance Period Primary Pop | — | 11/227 (4.8%) | 122/227 (53.7%) |
| Ixe/Ixe Q4W - Maintenance Period Primary Pop | — | 14/229 (6.1%) | 115/229 (50.2%) |
| Placebo Resp/Placebo - Maintenance Period Secondary Pop | — | 0/16 (0%) | 8/16 (50%) |
| Placebo Non-Resp/Ixe Q4W - Maintenance Period Secondary Pop | — | 24/391 (6.1%) | 211/391 (54%) |
| Ixe Q4W Non-Resp/Ixe Q4W - Maintenance Period Secondary Pop | — | 8/78 (10.3%) | 55/78 (70.5%) |
| Q2W Non-Resp/Q4W - Maintenance Period Secondary Pop | — | 3/62 (4.8%) | 34/62 (54.8%) |
| Ixe Q4W - Maintenance Period Relapse Pop | — | 11/348 (3.2%) | 114/348 (32.8%) |
| Placebo Long-Term Extension | — | 1/26 (3.8%) | 8/26 (30.8%) |
| Ixe Long-Term Extension | — | 134/1,054 (12.7%) | 414/1,054 (39.3%) |
| Total Ixe Long-Term Extension | — | 134/1,075 (12.5%) | 414/1,075 (38.5%) |
| Placebo Post-Treatment Follow-Up | — | 2/18 (11.1%) | 3/18 (16.7%) |
| Ixe Q12W Post-Treatment Follow-Up | — | 0/25 (0%) | 2/25 (8%) |
| Ixe Q4W Post Treatment Follow-Up | — | 13/700 (1.9%) | 33/700 (4.7%) |
| Ixe Q2W Post-Treatment Follow-Up | — | 6/285 (2.1%) | 15/285 (5.3%) |
| Event | Placebo - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period | Ixe/Placebo- Maintenance Period Primary Pop | Ixe/Ixe Q12W - Maintenance Period Primary Pop | Ixe/Ixe Q4W - Maintenance Period Primary Pop | Placebo Resp/Placebo - Maintenance Period Secondary Pop | Placebo Non-Resp/Ixe Q4W - Maintenance Period Secondary Pop | Ixe Q4W Non-Resp/Ixe Q4W - Maintenance Period Secondary Pop | Q2W Non-Resp/Q4W - Maintenance Period Secondary Pop | Ixe Q4W - Maintenance Period Relapse Pop | Placebo Long-Term Extension | Ixe Long-Term Extension | Total Ixe Long-Term Extension | Placebo Post-Treatment Follow-Up | Ixe Q12W Post-Treatment Follow-Up | Ixe Q4W Post Treatment Follow-Up | Ixe Q2W Post-Treatment Follow-Up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EndometritisInfections and infestations | 0/128 | 0/143 | 0/142 | 0/72 | 0/77 | 0/73 | 0/6 | 0/115 | 0/24 | 0/21 | 0/107 | 0/11 | 0/323 | 0/332 | 1/5 | 0/15 | 0/215 | 0/78 |
| Lacunar infarctionNervous system disorders | 0/431 | 0/432 | 0/433 | 0/226 | 0/227 | 0/229 | 0/16 | 0/391 | 0/78 | 0/62 | 0/348 | 0/26 | 0/1054 | 0/1075 | 1/18 | 0/25 | 0/700 | 0/285 |
| FallInjury, poisoning and procedural complications | 0/431 | 0/432 | 0/433 | 1/226 | 0/227 | 1/229 | 0/16 | 1/391 | 0/78 | 0/62 | 1/348 | 1/26 | 2/1054 | 2/1075 | 0/18 | 0/25 | 0/700 | 0/285 |
| Fibula fractureInjury, poisoning and procedural complications | 0/431 | 0/432 | 0/433 | 0/226 | 0/227 | 0/229 | 0/16 | 0/391 | 0/78 | 0/62 | 0/348 | 1/26 | 0/1054 | 0/1075 | 0/18 | 0/25 | 0/700 | 0/285 |
| Arteriospasm coronaryCardiac disorders | 0/431 | 0/432 | 0/433 | 0/226 | 0/227 | 0/229 | 0/16 | 0/391 | 0/78 | 1/62 | 0/348 | 0/26 | 0/1054 | 0/1075 | 0/18 | 0/25 | 0/700 | 0/285 |
| TinnitusEar and labyrinth disorders | 0/431 | 0/432 | 0/433 | 0/226 | 0/227 | 0/229 | 0/16 | 0/391 | 0/78 | 1/62 | 0/348 | 0/26 | 0/1054 | 0/1075 | 0/18 | 0/25 | 0/700 | 0/285 |
| Gastric ulcerGastrointestinal disorders | 0/431 | 0/432 | 0/433 | 0/226 | 0/227 | 0/229 | 0/16 | 0/391 | 0/78 | 1/62 | 0/348 | 0/26 | 0/1054 | 0/1075 | 0/18 | 0/25 | 0/700 | 0/285 |
| Mitral valve incompetenceCardiac disorders | 0/431 | 0/432 | 0/433 | 0/226 | 0/227 | 0/229 | 0/16 | 0/391 | 1/78 | 0/62 | 0/348 | 0/26 | 0/1054 | 0/1075 | 0/18 | 0/25 | 0/700 | 0/285 |
| Congenital pyelocaliectasisCongenital, familial and genetic disorders | 0/431 | 0/432 | 0/433 | 0/226 | 0/227 | 0/229 | 0/16 | 0/391 | 1/78 | 0/62 | 0/348 | 0/26 | 0/1054 | 0/1075 | 0/18 | 0/25 | 0/700 | 0/285 |
| Abdominal pain upperGastrointestinal disorders | 0/431 | 0/432 | 0/433 | 0/226 | 0/227 | 0/229 | 0/16 | 0/391 | 1/78 | 0/62 | 0/348 | 0/26 | 1/1054 | 1/1075 | 0/18 | 0/25 | 0/700 | 0/285 |
| Event | Placebo - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period | Ixe/Placebo- Maintenance Period Primary Pop | Ixe/Ixe Q12W - Maintenance Period Primary Pop | Ixe/Ixe Q4W - Maintenance Period Primary Pop | Placebo Resp/Placebo - Maintenance Period Secondary Pop | Placebo Non-Resp/Ixe Q4W - Maintenance Period Secondary Pop | Ixe Q4W Non-Resp/Ixe Q4W - Maintenance Period Secondary Pop | Q2W Non-Resp/Q4W - Maintenance Period Secondary Pop | Ixe Q4W - Maintenance Period Relapse Pop | Placebo Long-Term Extension | Ixe Long-Term Extension | Total Ixe Long-Term Extension | Placebo Post-Treatment Follow-Up | Ixe Q12W Post-Treatment Follow-Up | Ixe Q4W Post Treatment Follow-Up | Ixe Q2W Post-Treatment Follow-Up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 41/431 | 45/432 | 49/433 | 26/226 | 41/227 | 51/229 | 0/16 | 77/391 | 19/78 | 11/62 | 37/348 | 4/26 | 178/1054 | 178/1075 | 0/18 | 0/25 | 9/700 | 1/285 |
| Upper respiratory tract infectionInfections and infestations | 16/431 | 20/432 | 24/433 | 18/226 | 20/227 | 18/229 | 2/16 | 53/391 | 8/78 | 4/62 | 18/348 | 2/26 | 89/1054 | 89/1075 | 0/18 | 0/25 | 1/700 | 0/285 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 9/431 | 4/432 | 9/433 | 6/226 | 13/227 | 13/229 | 0/16 | 14/391 | 8/78 | 3/62 | 4/348 | 1/26 | 54/1054 | 54/1075 | 0/18 | 0/25 | 3/700 | 1/285 |
| Injection site reactionGeneral disorders | 5/431 | 27/432 | 42/433 | 2/226 | 7/227 | 12/229 | 0/16 | 36/391 | 7/78 | 2/62 | 13/348 | 0/26 | 27/1054 | 27/1075 | 0/18 | 0/25 | 0/700 | 0/285 |
| Back painMusculoskeletal and connective tissue disorders | 4/431 | 6/432 | 4/433 | 7/226 | 13/227 | 6/229 | 0/16 | 16/391 | 1/78 | 6/62 | 6/348 | 0/26 | 45/1054 | 45/1075 | 1/18 | 0/25 | 1/700 | 0/285 |
| PsoriasisSkin and subcutaneous tissue disorders | 16/431 | 2/432 | 4/433 | 5/226 | 6/227 | 2/229 | 1/16 | 4/391 | 2/78 | 1/62 | 4/348 | 0/26 | 21/1054 | 21/1075 | 0/18 | 2/25 | 11/700 | 5/285 |
| InfluenzaInfections and infestations | 0/431 | 4/432 | 2/433 | 4/226 | 8/227 | 7/229 | 0/16 | 7/391 | 2/78 | 2/62 | 3/348 | 2/26 | 28/1054 | 28/1075 | 0/18 | 0/25 | 3/700 | 2/285 |
| HeadacheNervous system disorders | 15/431 | 16/432 | 18/433 | 5/226 | 16/227 | 8/229 | 0/16 | 20/391 | 6/78 | 2/62 | 6/348 | 0/26 | 30/1054 | 30/1075 | 0/18 | 0/25 | 1/700 | 0/285 |
| Injection site erythemaGeneral disorders | 0/431 | 18/432 | 28/433 | 0/226 | 3/227 | 5/229 | 0/16 | 13/391 | 3/78 | 0/62 | 2/348 | 0/26 | 3/1054 | 3/1075 | 0/18 | 0/25 | 0/700 | 0/285 |
| CellulitisInfections and infestations | 0/431 | 1/432 | 0/433 | 0/226 | 1/227 | 2/229 | 0/16 | 4/391 | 5/78 | 0/62 | 3/348 | 0/26 | 14/1054 | 14/1075 | 0/18 | 0/25 | 0/700 | 1/285 |
All randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Placebo | Ixe Q4W | Ixe Q2W | Total |
|---|---|---|---|---|
| Mean | 46.4 ± 13.40 | 45.6 ± 12.95 | 45.1 ± 12.40 | 45.7 ± 12.93 |
| Sex: Female, Male(Participants) | Placebo | Ixe Q4W | Ixe Q2W | Total |
|---|---|---|---|---|
| Female | 128 | 143 | 142 | 413 |
| Male | 303 | 289 | 291 | 883 |
| Region of Enrollment(Participants) | Placebo | Ixe Q4W | Ixe Q2W | Total |
|---|---|---|---|---|
| Canada | 77 | 69 | 66 | 212 |
| Romania | 8 | 3 | 2 | 13 |
| Hungary | 23 | 17 | 26 | 66 |
| United States | 146 | 156 | 159 | 461 |
| Japan | 13 | 12 | 8 | 33 |
| Denmark | 4 | 4 | 8 | 16 |
| Poland | 43 | 41 | 55 | 139 |
| Italy | 3 | 2 | 1 | 6 |
| United Kingdom | 7 | 7 | 7 | 21 |
| Australia | 19 | 15 | 8 | 42 |
| Germany | 88 | 106 | 93 | 287 |
| Static Physician Global Assessment (sPGA)(Participants) | Placebo | Ixe Q4W | Ixe Q2W | Total |
|---|---|---|---|---|
| sPGA=3 | 204 | 197 | 231 | 632 |
| sPGA=4, 5 | 227 | 235 | 202 | 664 |
| Psoriasis Area and Severity Index (PASI)(units on a scale) | Placebo | Ixe Q4W | Ixe Q2W | Total |
|---|---|---|---|---|
| Mean | 20.32 ± 8.641 | 20.03 ± 7.304 | 20.09 ± 7.992 | 20.15 ± 7.992 |
| Itch Numeric Rating Scale (NRS)(units on a scale) | Placebo | Ixe Q4W | Ixe Q2W | Total |
|---|---|---|---|---|
| Mean | 7.0 ± 2.58 | 7.0 ± 2.50 | 7.2 ± 2.39 | 7.1 ± 2.49 |
| Dermatology-Specific Quality of Life Index (DLQI) Score(units on a scale) | Placebo | Ixe Q4W | Ixe Q2W | Total |
|---|---|---|---|---|
| Mean | 12.8 ± 7.11 | 13.2 ± 7.02 | 13.4 ± 7.02 | 13.1 ± 7.05 |
| Nail Psoriasis Severity Index (NAPSI)(units on a scale) | Placebo | Ixe Q4W | Ixe Q2W | Total |
|---|---|---|---|---|
| Mean | 26.9 ± 20.492 | 24.12 ± 18.243 | 24.64 ± 18.916 | 24.95 ± 19.238 |
6 further baseline measures are reported on the registry.
Showing the first 100 of 104 sites across 11 countries. Choose a country and city above to see the rest.
Ran from Nov 2011 to primary completion in Jun 2014, 31 months.
Results were first posted in May 2016, 1 year 11 months after primary completion. A results delay was requested in Sep 2014.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 31 months is above that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ixekizumab